Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Clinical Study to Evaluate Safety, Tolerance，Pharmacokinetics and Efficacy of SY-007 After Intravenous Injection in Acute Ischemic Stroke Subjects

NCT04891913 is registered in ClinicalTrials.gov with Suzhou Yabao Pharmaceutical R&D Co., Ltd. as lead sponsor.

NCT NCT04891913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04891913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Clinical Study to Evaluate Safety, Tolerance，Pharmacokinetics and Efficacy of SY-007 After Intravenous Injection in Acute Ischemic Stroke Subjects
Lead sponsor
Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Phase
Phase 1
Overall status
Suspended
Start date
July 1, 2023
Completion date
December 25, 2023
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke